Antithymocyte globulin versus basiliximab in renal transplantation.
Killen
John P
JP
Chadban
Steven
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000077552:Basiliximab; D002102:Cadaver; D051799:Delayed Graft Function; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab